Anthem Biosciences IPO Review

Anthem Biosciences is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (“CRDMO”) with fully integrated operations spanning across drug discovery, development and manufacturing. They are one of the few companies in India with integrated New Chemical Entity (“NCE”) and New Biological Entity (“NBE”) capabilities across drug discovery, development, and commercial manufacturing.

The company is led by the professional and experienced founding team and senior management personnel, including our Founder and CEO, Mr. Ajay Bhardwaj, each of whom have been involved in the Company since inception and individually possesses industry experience of more than 25 years.

The Revenues from operations for the Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 19,302.85 Million, ₹ 14,830.69 Million and ₹ 11,339.92 Million. The EBITDA for the Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 7,565.68 Million, ₹ 5,686.77 Million and ₹ 5,677.56 Million. The Profit after Tax for the Fiscals ended on Mar 31, 2025, 2024 and 2023 were were ₹ 4,512.59 Million, ₹ 3,673.10 Million and ₹ 3,581.85 Million respectively. This indicates a steady growth in financial performance.

The Company Key Performance Indicates the pre-issue EPS of ₹ 8.07 and post-issue EPS of ₹ 8.04 for FY24. The pre-issue P/E ratio is 70.63x, while the post-issue P/E ratio is 70.94x against the Industry P/E ratio is 81x. The company's ROCE for FY24 is 27.64%, ROE for FY24 is 20.82% and RoNW is 20.82%. These metrics suggest that the IPO is fairly priced.

The Grey Market Premium (GMP) of Anthem Biosciences showing listing gains of 12.28 %.Given the company's financial performance and the valuation of the IPO, we recommend Investors to Apply to the Anthem Biosciences Limited IPO for Listing gain.

Disclaimer: The information provided in this IPO review is for educational and informational purposes only and should not be construed as financial advice or an offer to buy or sell securities. The review must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. The content is based on publicly available information and market perceptions as of the date of publication and is subject to change. Neither the author nor the website is responsible for any losses or damages arising from the use of this information. 1.“Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.” 2. “Investment in securities market are subject to market risks. Read all the related documents carefully before investing.” 3. To read the Disclaimers, Disclosures, Investor Charter, Investor Complaints please visit our website abhayvarn.com

About the Author
CA Abhay Kumar (Also known as  CA Abhay Varn) is a qualified Chartered Accountant by profession and cleared CA at age 21. He is a SEBI Registered Research Analyst with Registration Number - INH300008465. He Possesses 8+ years of experience in the Stock Market Field and has also worked in Big CA firms.